Pharmaceutical company Pfizer reported that its COVID-19 vaccine, Comirnaty, has demonstrated 90.7 percent efficacy against symptomatic disease in children between 5 and 11 years of age, data that comes to light just days before the FDA can give it the green light.
Through a comunicado, Pfizer specified that two primary doses of 10 micrograms of its vaccine